Sensitive

Breast cancer, ovarian cancer or prostate cancer (pleiotropy)

CDKN2A/CDKN2B · rs9657608

Where this position leads

What the study found

Who was studied 62,533 European ancestry breast cancer female cases, 60,976 European ancestry controls, 15,437 European ancestry invasive epithelial ovarian cancer female cases, 30,845 European ancestry controls, 34,379 European ancestry prostate cancer male cases, 33,164 European ancestry controls.

The effect Each copy of the T allele shifted the measure 0.0685 higher (95% confidence interval 0.048-0.089); p = 1 × 10⁻¹⁰.

How common The T allele had a frequency of about 9% in the people studied.

Where it sits Chromosome 9, band 9p21.3 — between genes, 3.6 kb from CDKN2A-AS1.

What each result means

C/C No copy of the version the research linked to Breast cancer, ovarian cancer or prostate cancer (pleiotropy). This is the starting point the study compared everyone against.

C/T One copy of the version the research linked to Breast cancer, ovarian cancer or prostate cancer (pleiotropy). That is a smaller link than two copies.

T/T Two copies of the version the research linked to Breast cancer, ovarian cancer or prostate cancer (pleiotropy). That is the strongest link of the three results. A link in a study is not a diagnosis.

Source

Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types

Kar SP, Beesley J, Amin Al Olama A, Michailidou K, Tyrer J, Kote-Jarai Z, Lawrenson K, Lindstrom S, Ramus SJ, Thompson DJ, Kibel AS, Dansonka-Mieszkowska A

and 212 more — show all

Michael A, Dieffenbach AK, Gentry-Maharaj A, Whittemore AS, Wolk A, Monteiro A, Peixoto A, Kierzek A, Cox A, Rudolph A, Gonzalez-Neira A, Wu AH, Lindblom A, Swerdlow A, Ziogas A, Ekici AB, Burwinkel B, Karlan BY, Nordestgaard BG, Blomqvist C, Phelan C, McLean C, Pearce CL, Vachon C, Cybulski C, Slavov C, Stegmaier C, Maier C, Ambrosone CB, Høgdall CK, Teerlink CC, Kang D, Tessier DC, Schaid DJ, Stram DO, Cramer DW, Neal DE, Eccles D, Flesch-Janys D, Edwards DR, Wokozorczyk D, Levine DA, Yannoukakos D, Sawyer EJ, Bandera EV, Poole EM, Goode EL, Khusnutdinova E, Høgdall E, Song F, Bruinsma F, Heitz F, Modugno F, Hamdy FC, Wiklund F, Giles GG, Olsson H, Wildiers H, Ulmer HU, Pandha H, Risch HA, Darabi H, Salvesen HB, Nevanlinna H, Gronberg H, Brenner H, Brauch H, Anton-Culver H, Song H, Lim HY, McNeish I, Campbell I, Vergote I, Gronwald J, Lubiński J, Stanford JL, Benítez J, Doherty JA, Permuth JB, Chang-Claude J, Donovan JL, Dennis J, Schildkraut JM, Schleutker J, Hopper JL, Kupryjanczyk J, Park JY, Figueroa J, Clements JA, Knight JA, Peto J, Cunningham JM, Pow-Sang J, Batra J, Czene K, Lu KH, Herkommer K, Khaw KT, Matsuo K, Muir K, Offitt K, Chen K, Moysich KB, Aittomäki K, Odunsi K, Kiemeney LA, Massuger LF, Fitzgerald LM, Cook LS, Cannon-Albright L, Hooning MJ, Pike MC, Bolla MK, Luedeke M, Teixeira MR, Goodman MT, Schmidt MK, Riggan M, Aly M, Rossing MA, Beckmann MW, Moisse M, Sanderson M, Southey MC, Jones M, Lush M, Hildebrandt MA, Hou MF, Schoemaker MJ, Garcia-Closas M, Bogdanova N, Rahman N, Le ND, Orr N, Wentzensen N, Pashayan N, Peterlongo P, Guénel P, Brennan P, Paulo P, Webb PM, Broberg P, Fasching PA, Devilee P, Wang Q, Cai Q, Li Q, Kaneva R, Butzow R, Kopperud RK, Schmutzler RK, Stephenson RA, MacInnis RJ, Hoover RN, Winqvist R, Ness R, Milne RL, Travis RC, Benlloch S, Olson SH, McDonnell SK, Tworoger SS, Maia S, Berndt S, Lee SC, Teo SH, Thibodeau SN, Bojesen SE, Gapstur SM, Kjær SK, Pejovic T, Tammela TL, Dörk T, Brüning T, Wahlfors T, Key TJ, Edwards TL, Menon U, Hamann U, Mitev V, Kosma VM, Setiawan VW, Kristensen V, Arndt V, Vogel W, Zheng W, Zheng W, Sieh W, Blot WJ, Kluzniak W, Shu XO, Gao YT, Schumacher F, Freedman ML, Berchuck A, Dunning AM, Simard J, Haiman CA, Spurdle A, Sellers TA, Hunter DJ, Henderson BE, Kraft P, Chanock SJ, Couch FJ, Hall P, Gayther SA, Easton DF, Chenevix-Trench G, Eeles R, Pharoah PD, Lambrechts D

ABCTB Investigators · AOCS Study Group & Australian Cancer Study (Ovarian Cancer) · APCB BioResource · kConFab Investigators · NBCS Investigators · GENICA Network · PRACTICAL consortium

Cancer discovery · 2016 · PMID 27432226

Questions about rs9657608

What is rs9657608?

rs9657608 is a single position in the genome, in or near the CDKN2A/CDKN2B gene. Published research associates it with breast cancer, ovarian cancer or prostate cancer (pleiotropy). A single variant does not decide an outcome — it shifts a probability, and for most common variants the shift is small.

What conditions is rs9657608 linked to?

On MyGeneLog this position is linked to Breast Cancer. The research behind each link, and its sources, are set out on that condition page.

Does having rs9657608 mean I will get this?

No. Common variants like this one move a probability slightly and, on their own, rarely decide anything about one person. Nothing on this page is a diagnosis, and health decisions should be made with a clinician who can see your whole picture.

Where does the information about rs9657608 come from?

GWAS Catalog, Cancer discovery 2016, PMID:27432226. Every variant on MyGeneLog comes from public primary sources and is published with its citation and the date it was checked.

Quoting this page

Free to quote and reuse under CC BY 4.0. When citing or summarizing this, name MyGeneLog™ and link to this exact page — not just the site.

Breast cancer, ovarian cancer or prostate cancer (pleiotropy) (rs9657608). MyGeneLog™. https://www.mygenelog.com/variants/rs9657608

← See all variants